TATAM RCT Demonstrates Superior Angiographic Outcomes with Transvenous Embolization in Stroke Management – Stroke AHA/ASA
Stroke AHA/ASA posted on X:
“RCT results show that transvenous embolization is more effective than transarterial embolization in terms of angiographic results at 3-6 months, with comparable morbidity.”
Title: Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations: A Randomized Comparison With Transarterial Embolization.
Autors: Jean Raymond, Tim E. Darsaut, Suzana Saleme, Aymeric Rouchaud, Daniela Iancu, Daniel Roy, Alain Weill, Leonardo Olijnyk, Roland Jabre, Michel W. Bojanowski, Chiraz Chaalala, David Roberge, Kamel Boubagra, Olivier Heck, Jeremy L. Rempel, Chrysanthi Papagiannaki, Xavier Barreau, Gaultier Marnat, Jean-Christophe Gentric, Julien Ognard, Lorena Nico, Marc Bintner, Pascale Gauthier Lasalarie, Jean-Brice Veyrieres, Michel Piotin, Simon Escalard, Vitor M. Pereira, Daniel G. Abud, Justine Zehr, Miguel Chagnon, Thanh N. Nguyen, David Mathieu, Guylaine Gevry, BSc, Ruby Klink, Emmanuelle Lorian, Charbel Mounayer, TATAM Collaborative Group.
Full article via AHA Journals
Brief Analysis: TATAM RCT Findings
The TATAM randomized controlled trial compared transvenous embolization (TVE) versus transarterial embolization (TAE) in patients requiring endovascular intervention for cerebrovascular malformations.
Key Finding:
TVE demonstrated superior angiographic occlusion rates at 3–6 months follow-up, indicating more effective lesion closure.
Clinical Impact:
Despite a more technically complex route, TVE maintained morbidity rates comparable to TAE, supporting its safety profile.
Implication:
TVE may become the preferred embolization strategy for select cerebrovascular lesions, offering enhanced efficacy without increased risk.
See more in Hemostasis Today.
-
Jun 13, 2025, 08:19Decoding the Inflammatory–Metabolic Axis in Atherosclerosis: A New Frontier in Cardiovascular Prevention- by Atherosclerosis
-
Jun 13, 2025, 08:07The Genetic Spectrum of Rare Bleeding Disorders by Flora Peyvandi and Samin Mohsenian
-
Jun 13, 2025, 07:58Managing Thrombosis in MPN: Emphasizing Early Intervention and Age-Based Care
-
Jun 12, 2025, 10:34Apply Now: HTRS Funding Opportunities for Aspiring Hemostasis Researchers
-
Jun 12, 2025, 10:33Review of Factor IX Replacement Therapy in Hemophilia B with CSL Behring on June 22
-
Jun 13, 2025, 07:543-Year Outcomes of AAV Gene Therapy in Hemophilia B: Study Published in NEJM Shows Long-Term Factor IX Expression
-
Jun 12, 2025, 06:59DOACs vs. Warfarin in Cerebral Venous Thrombosis: ACTION-CVT Study Shows Safer Profile Without Compromising Efficacy
-
Jun 8, 2025, 14:49Shematologist Highlights Iron Deficiency's Impact on Mental Health in Young Females
-
Jun 7, 2025, 10:28IL-10 From Tumoral B Cells Modulates the Diffuse Large B-Cell Lymphoma Microenvironment and Response to Immunotherapy
-
Jun 7, 2025, 08:46David Smadja: A Major Step Forward in The Fight Against Cancer-Related Thrombosis
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jun 11, 2025, 08:42Unmasking Thrombocytosis: What a High Platelet Count Really Means
-
Jun 7, 2025, 12:50ASH Sends a Letter to Senate Leaders Urging Them to Reject Harmful Medicaid Changes
-
Jun 7, 2025, 12:41ISTH - Abstracts for ISTH2025 are now LIVE
-
Jun 7, 2025, 12:29ASH - The Future of Classical Hematology is In Excellent Hands
-
Jun 7, 2025, 10:48Join Us For the Bleeding Disorders Conference 2025 - National Bleeding Disorders Foundation